The DOI matches its Crossref record; 582 of the 582 references it cites were found in a registry or an index.
Inhibition and induction of human cytochrome P450 enzymes: current status
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Novel Procedure for Modeling Ligand/Receptor Induced Fit Effects
Sherman, W., Day, T., Jacobson, M. P., Friesner, R. A., & Farid, R. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050540c · Cited by 2,031
Cytochrome P450 and Chemical Toxicology
Guengerich, F. P. (2008) · Chemical Research in Toxicology · doi:10.1021/tx700079z · Cited by 1,725
Lehmann, J. M., McKee, D. D., Watson, M. A., Willson, T. M., Moore, J. T., & Kliewer, S. A. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3703 · Cited by 1,576
An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway
Kliewer, S. A., Moore, J. T., Wade, L., Staudinger, J. L., Watson, M. A., Jones, S. A., McKee, D. D., Oliver, B. B., Willson, T. M., Zetterström, R. H., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)80900-9 · Cited by 1,539
The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity
Staudinger, J. L., Goodwin, B., Jones, S. A., Hawkins-Brown, D., MacKenzie, K. I., LaTour, A., Liu, Y., Klaassen, C. D., Brown, K. K., Reinhard, J., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051551698 · Cited by 1,379
Metabolism and Disposition Kinetics of Nicotine
Hukkanen, J., Jacob, P., & Benowitz, N. L. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.1.3 · Cited by 1,321
Self-citationInfection of a human hepatoma cell line by hepatitis B virus
Gripon, P., Rumin, S., Urban, S., Le Seyec, J., Glaise, D., Cannie, I., Guyomard, C., Lucas, J., Trepo, C., & Guguen-Guillouzo, C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.232137699 · Cited by 1,282
Burke, M. D., Thompson, S., Elcombe, C. R., Halpert, J., Haaparanta, T., & Mayer, R. T. (1985) · Biochemical Pharmacology · doi:10.1016/0006-2952(85)90355-7 · Cited by 1,275
Aithal, G. P., Day, C. P., Kesteven, P. J., & Daly, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)04474-2 · Cited by 1,243
Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects
Guengerich, F. P., Kim, D. H., & Iwasaki, M. (1991) · Chemical Research in Toxicology · doi:10.1021/tx00020a008 · Cited by 1,169
Ingelman-Sundberg, M., Sim, S. C., Gomez, A., & Rodriguez-Antona, C. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.004 · Cited by 1,166
Nelson, D. R., Zeldin, D. C., Hoffman, S. M., Maltais, L. J., Wain, H. M., & Nebert, D. W. (2004) · Pharmacogenetics · doi:10.1097/00008571-200401000-00001 · Cited by 1,027
Timing of new black box warnings and withdrawals for prescription medications
Lasser, K. E. (2002) · JAMA · doi:10.1001/jama.287.17.2215 · Cited by 1,005
Nebert, D. W., & Dalton, T. P. (2006) · Nature Reviews Cancer · doi:10.1038/nrc2015 · Cited by 958
Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
Desta, Z., Zhao, X., Shin, J.-G., & Flockhart, D. A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241120-00002 · Cited by 942
SXR, a novel steroid and xenobioticsensing nuclear receptor
Blumberg, B., Sabbagh, W., Juguilon, H., Bolado, J., van Meter, C. M., Ong, E. S., & Evans, R. M. (1998) · Genes & Development · doi:10.1101/gad.12.20.3195 · Cited by 919
Predicting in vivo drug interactions from in vitro drug discovery data
Wienkers, L. C., & Heath, T. G. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1851 · Cited by 904
Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1.
Shimada, T., Hayes, C. L., Yamazaki, H., Amin, S., Hecht, S. S., Guengerich, F. P., & Sutter, T. R. (1996) · PubMed · Cited by 895
Identification of a human nuclear receptor defines a new signaling pathway for CYP 3 A induction
Bertilsson, G., Heidrich, J., Svensson, K., Åsman, M., Jendeberg, L., Sydow-Bäckman, M., Ohlsson, R., Postlind, H., Blomquist, P., & Berkenstam, A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.21.12208 · Cited by 872
THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
Paine, M. F., Hart, H. L., Ludington, S. S., Haining, R. L., Rettie, A. E., & Zeldin, D. C. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008672 · Cited by 870
Wacher, V. J., Wu, C., & Benet, L. Z. (1995) · Molecular Carcinogenesis · doi:10.1002/mc.2940130302 · Cited by 857
Cytochrome P4502C9: an enzyme of major importance in human drug metabolism
Miners, J. O., & Birkett, D. J. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00721.x · Cited by 844
Robust expansion of human hepatocytes in Fah−/−/Rag2−/−/Il2rg−/− mice
Azuma, H., Paulk, N., Ranade, A., Dorrell, C., Al-Dhalimy, M., Ellis, E., Strom, S., Kay, M. A., Finegold, M., & Grompe, M. (2007) · Nature Biotechnology · doi:10.1038/nbt1326 · Cited by 835
Inhibition and Induction of Cytochrome P450 and the Clinical Implications
Lin, J. H., & Lu, A. Y. H. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835050-00003 · Cited by 829
Ding, X., & Kaminsky, L. S. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140251 · Cited by 822
Summary of information on human CYP enzymes: human P450 metabolism data
Rendic, S. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001392 · Cited by 820
Moore, L. B., Parks, D. J., Jones, S. A., Bledsoe, R. K., Consler, T. G., Stimmel, J. B., Goodwin, B., Liddle, C., Blanchard, S. G., Willson, T. M., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001215200 · Cited by 815
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry
Zanger, U. M., Raimundo, S., & Eichelbaum, M. (2004) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-003-0832-2 · Cited by 795
Bjornsson, T. D., Callaghan, J. T., Einolf, H. J., Fischer, V., Gan, L., Grimm, S., Kao, J., King, S. P., Miwa, G., Ni, L., et al. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.7.815 · Cited by 792
Pharmacokinetic Interactions with Rifampicin: Clinical Relevance
Niemi, M., Backman, J. T., Fromm, M. F., Neuvonen, P. J., & Kivist??, K. T. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342090-00003 · Cited by 764
The Human Nuclear Xenobiotic Receptor PXR: Structural Determinants of Directed Promiscuity
Watkins, R. E., Wisely, G. B., Moore, L. B., Collins, J. L., Lambert, M. H., Williams, S. P., Willson, T. M., Kliewer, S. A., & Redinbo, M. R. (2001) · Science · doi:10.1126/science.1060762 · Cited by 760
An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids
Xie, W., Radominska-Pandya, A., Shi, Y., Simon, C. M., Nelson, M. C., Ong, E. S., Waxman, D. J., & Evans, R. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051014398 · Cited by 757
Sachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00898.x · Cited by 751
Hewitt, N. J., Gómez Lechón, M. J., Houston, J. B., Hallifax, D., Brown, H. S., Maurel, P., Kenna, J. G., Gustavsson, L., Lohmann, C., Skonberg, C., et al. (2007) · Drug Metabolism Reviews · doi:10.1080/03602530601093489 · Cited by 735
Pharmacogenomics and Individualized Drug Therapy
Eichelbaum, M., Ingelman-Sundberg, M., & Evans, W. E. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104724 · Cited by 720
The Search for Endogenous Activators of the Aryl Hydrocarbon Receptor
Nguyen, L. P., & Bradfield, C. A. (2008) · Chemical Research in Toxicology · doi:10.1021/tx7001965 · Cited by 709
Aninat, C., Piton, A., Glaise, D., Le Charpentier, T., Langouët, S., Morel, F., Guguen-Guillouzo, C., & Guillouzo, A. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.006759 · Cited by 703
Honkakoski, P., Zelko, I., Sueyoshi, T., & Negishi, M. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.10.5652 · Cited by 700
Self-citationThe Pregnane X Receptor: A Promiscuous Xenobiotic Receptor That Has Diverged during Evolution
Jones, S. A., Moore, L. B., Shenk, J. L., Wisely, G. B., Hamilton, G. A., McKee, D. D., Tomkinson, N. C. O., LeCluyse, E. L., Lambert, M. H., Willson, T. M., et al. (2000) · Molecular Endocrinology · doi:10.1210/me.14.1.27 · Cited by 672
The Repressed Nuclear Receptor CAR Responds to Phenobarbital in Activating the Human CYP2B6 Gene
Sueyoshi, T., Kawamoto, T., Zelko, I., Honkakoski, P., & Negishi, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6043 · Cited by 668
Self-citationHumanized xenobiotic response in mice expressing nuclear receptor SXR
Xie, W., Barwick, J. L., Downes, M., Blumberg, B., Simon, C. M., Nelson, M. C., Neuschwander-Tetri, B. A., Brunt, E. M., Guzelian, P. S., & Evans, R. M. (2000) · Nature · doi:10.1038/35019116 · Cited by 660
Goodwin, B., Hodgson, E., & Liddle, C. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12400-5 · Cited by 646
A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2)
Hsiang, B., Zhu, Y., Wang, Z., Wu, Y., Sasseville, V., Yang, W.-P., & Kirchgessner, T. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.37161 · Cited by 641
Butler, M. A., Iwasaki, M., Guengerich, F. P., & Kadlubar, F. F. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.20.7696 · Cited by 638
Directed differentiation of human embryonic stem cells into functional hepatic cells†
Cai, J., Zhao, Y., Liu, Y., Ye, F., Song, Z., Qin, H., Meng, S., Chen, Y., Zhou, R., Song, X., et al. (2007) · Hepatology · doi:10.1002/hep.21582 · Cited by 634
Dresser, G. K., Bailey, D. G., Leake, B. F., Schwarz, U. I., Dawson, P. A., Freeman, D. J., & Kim, R. B. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.121152 · Cited by 606
Newton, D. J., Wang, R. W., & Lu, A. Y. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06500-6 · Cited by 605
Clinically relevant drug interactions with antiepileptic drugs
Perucca, E. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02529.x · Cited by 602
OATP and P-Glycoprotein Transporters Mediate the Cellular Uptake and Excretion of Fexofenadine
Cvetkovic, M., Leake, B., Fromm, M. F., Wilkinson, G. R., & Kim, R. B. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15235-x · Cited by 597
Ward, B. A., Gorski, J. C., Jones, D. R., Hall, S. D., Flockhart, D. A., & Desta, Z. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049601 · Cited by 593
Bjeldanes, L. F., Kim, J. Y., Grose, K. R., Bartholomew, J. C., & Bradfield, C. A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.21.9543 · Cited by 588
Cytochrome P450 3A: Ontogeny and Drug Disposition
de Wildt, S. N., Kearns, G. L., Leeder, J. S., & van den Anker, J. N. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199937060-00004 · Cited by 586
Identification of a novel mechanism of regulation of Ah (dioxin) receptor function
Mimura, J., Ema, M., Sogawa, K., & Fujii-Kuriyama, Y. (1999) · Genes & Development · doi:10.1101/gad.13.1.20 · Cited by 585
Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling
Huang, S.-M., Temple, R., Throckmorton, D. C., & Lesko, L. J. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100054 · Cited by 579
Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1
Gonzalez, F. J. (2005) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2004.04.021 · Cited by 555
Near Completely Humanized Liver in Mice Shows Human-Type Metabolic Responses to Drugs
Tateno, C., Yoshizane, Y., Saito, N., Kataoka, M., Utoh, R., Yamasaki, C., Tachibana, A., Soeno, Y., Asahina, K., Hino, H., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63352-4 · Cited by 548
Westerink, W. M. A., & Schoonen, W. G. E. J. (2007) · Toxicology in Vitro · doi:10.1016/j.tiv.2007.05.014 · Cited by 544
Kronbach, T., Fischer, V., & Meyer, U. A. (1988) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1988.87 · Cited by 533
Simulation and prediction of in vivo drug metabolism in human populations from in vitro data
Rostami-Hodjegan, A., & Tucker, G. T. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2173 · Cited by 530
Oxidative Stress, Toxicology, and Pharmacology of CYP2E1
Caro, A. A., & Cederbaum, A. I. (2004) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121704 · Cited by 512
Ito, K., Iwatsubo, T., Kanamitsu, S., Ueda, K., Suzuki, H., & Sugiyama, Y. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01372-3 · Cited by 512
Nishizato, Y. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00060-2 · Cited by 511
Sutter, T. R., Tang, Y. M., Hayes, C. L., Wo, Y. Y., Jabs, E. W., Li, X., Yin, H., Cody, C. W., & Greenlee, W. F. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36803-5 · Cited by 508
VALIDATED ASSAYS FOR HUMAN CYTOCHROME P450 ACTIVITIES
Walsky, R. L., & Obach, R. S. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.6.647 · Cited by 507
Dai, D., Zeldin, D. C., Blaisdell, J. A., Chanas, B., Coulter, S. J., Ghanayem, B. I., & Goldstein, J. A. (2001) · Pharmacogenetics · doi:10.1097/00008571-200110000-00006 · Cited by 494
Female sex and oral contraceptive use accelerate nicotine metabolism
BENOWITZ, N., LESSOVSCHLAGGAR, C., SWAN, G., & JACOBIII, P. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.01.008 · Cited by 486
Ritonavir: Clinical Pharmacokinetics and Interactions with Other Anti-HIV Agents
Hsu, A., Granneman, G. R., & Bertz, R. J. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835040-00002 · Cited by 483
LeCluyse, E. L. (2001) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(01)00135-x · Cited by 477
Androstane metabolites bind to and deactivate the nuclear receptor CAR-β
Forman, B. M., Tzameli, I., Choi, H.-S., Chen, J., Simha, D., Seol, W., Evans, R. M., & Moore, D. D. (1998) · Nature · doi:10.1038/26996 · Cited by 476
Clinical consequences of cytochrome P450 2C9 polymorphisms
KIRCHHEINER, J., & BROCKMOLLER, J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.08.009 · Cited by 474
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7
Williams, J. A., Ring, B. J., Cantrell, V. E., Jones, D. R., Eckstein, J., Ruterbories, K., Hamman, M. A., Hall, S. D., & Wrighton, S. A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.8.883 · Cited by 471
Crewe, H., Lennard, M., Tucker, G., Woods, F., & Haddock, R. (1992) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1992.tb04134.x · Cited by 469
Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein
Kirn, R. B., Wandel, C., Leake, B., Cvetkovic, M., Fromm, M. F., Dempsey, P. J., Roden, M. M., Belas, F., Chaudhary, A. K., Roden, D. M., et al. (1999) · Pharmaceutical Research · doi:10.1023/a:1018877803319 · Cited by 454
A Major Role for CYP2A6 in Nicotine C-Oxidation by Human Liver Microsomes
Messina, E. S., Tyndale, R. F., & Sellers, E. M. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36947-2 · Cited by 453
Accelerated Metabolism of Nicotine and Cotinine in Pregnant Smokers
Dempsey, D., Jacob, P., & Benowitz, N. L. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.2.594 · Cited by 452
Luo, G., Cunningham, M., Kim, S., Burn, T., Lin, J., Sinz, M., Hamilton, G., Rizzo, C., Jolley, S., Gilbert, D., et al. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.7.795 · Cited by 442
The orphan nuclear receptor HNF4α determines PXR- and CAR-mediated xenobiotic induction of CYP3A4
Tirona, R. G., Lee, W., Leake, B. F., Lan, L.-B., Cline, C. B., Lamba, V., Parviz, F., Duncan, S. A., Inoue, Y., Gonzalez, F. J., et al. (2003) · Nature Medicine · doi:10.1038/nm815 · Cited by 440
The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions
Obach, R. S., Walsky, R. L., Venkatakrishnan, K., Gaman, E. A., Houston, J. B., & Tremaine, L. M. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.093229 · Cited by 433
Bertilsson, L. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199529030-00005 · Cited by 432
Microsomal Ethanol‐Oxidizing System (MEOS): The First 30 Years (1968‐1998)–A Review
Lieber, C. S. (1999) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.1999.tb04217.x · Cited by 426
CAR and PXR: The xenobiotic-sensing receptors☆
Timsit, Y. E., & Negishi, M. (2007) · Steroids · doi:10.1016/j.steroids.2006.12.006 · Cited by 423
Rodríguez-Antona, C., Donato, M. T., Boobis, A., Edwards, R. J., Watts, P. S., Castell, J. V., & Gómez-Lechón, M.-J. (2002) · Xenobiotica · doi:10.1080/00498250210128675 · Cited by 420
Role of human cytochrome P4502A6 in C-oxidation of nicotine.
Nakajima, M., Yamamoto, T., Nunoya, K., Yokoi, T., Nagashima, K., Inoue, K., Funae, Y., Shimada, N., Kamataki, T., & Kuroiwa, Y. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08453-3 · Cited by 418
Maglich, J. M., Parks, D. J., Moore, L. B., Collins, J. L., Goodwin, B., Billin, A. N., Stoltz, C. A., Kliewer, S. A., Lambert, M. H., Willson, T. M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300138200 · Cited by 416
Shitara, Y., Hirano, M., Sato, H., & Sugiyama, Y. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068536 · Cited by 407
Efficient Differentiation of Functional Hepatocytes from Human Embryonic Stem Cells
Agarwal, S., Holton, K. L., & Lanza, R. (2008) · Stem Cells · doi:10.1634/stemcells.2007-1102 · Cited by 405
Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3).
Wrighton, S. A., Brian, W. R., Sari, M. A., Iwasaki, M., Guengerich, F. P., Raucy, J. L., Molowa, D. T., & Vandenbranden, M. (1990) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09441-6 · Cited by 402
Hesse, L. M., Venkatakrishnan, K., Court, M. H., von Moltke, L. L., Duan, S. X., Shader, R. I., & Greenblatt, D. J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12046-9 · Cited by 397
Induction of bilirubin clearance by the constitutive androstane receptor (CAR)
Huang, W., Zhang, J., Chua, S. S., Qatanani, M., Han, Y., Granata, R., & Moore, D. D. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0630614100 · Cited by 390
PARKINSON, A. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.01.010 · Cited by 386
The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes
Yamano, S., Tatsuno, J., & Gonzalez, F. J. (1990) · Biochemistry · doi:10.1021/bi00457a031 · Cited by 383
Fluvoxamine is a potent inhibitor of cytochrome P4501A2
Brøsen, K., Skjelbo, E., Rasmussen, B. B., Poulsen, H. E., & Loft, S. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90272-x · Cited by 374
Regulation of the Human CYP2B6 Gene by the Nuclear Pregnane X Receptor
Goodwin, B., Moore, L. B., Stoltz, C. M., McKee, D. D., & Kliewer, S. A. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12603-x · Cited by 374
DNA adduct formation from tobacco-specific N-nitrosamines
Hecht, S. S. (1999) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(99)00014-7 · Cited by 371
McCarver, D. G., & Hines, R. N. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.2.361 · Cited by 366
The Ontogeny of Human Drug-Metabolizing Enzymes: Phase I Oxidative Enzymes
Hines, R. N., & McCarver, D. G. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.2.355 · Cited by 365
Bourrié, M., Meunier, V, Berger, Y., & Fabre, G. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12826-7 · Cited by 363
Inhibition and induction of human cytochrome P450 (CYP) enzymes
PELKONEN, O., MÄEENPÄEÄ, J., TAAVITSAINEN, P., RAUTIO, A., & RAUNIO, H. (1998) · Xenobiotica · doi:10.1080/004982598238886 · Cited by 358
Self-citationWu, C.-Y., Benet, L. Z., Hebert, M. F., Gupta, S. K., Rowland, M., Gomez, D. Y., & Wacher, V. J. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90168-x · Cited by 356
Moore, L. B., Maglich, J. M., McKee, D. D., Wisely, B., Willson, T. M., Kliewer, S. A., Lambert, M. H., & Moore, J. T. (2002) · Molecular Endocrinology · doi:10.1210/me.16.5.977 · Cited by 355
Faucette, S. R., Hawke, R. L., Lecluyse, E. L., Shord, S. S., Yan, B., Laethem, R. M., & Lindley, C. M. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12054-8 · Cited by 353
Cloning and expression of a human Ah receptor cDNA.
Dolwick, K. M., Schmidt, J. V., Carver, L. A., Swanson, H. I., & Bradfield, C. A. (1993) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13282-3 · Cited by 348
Watkins, P. B., Murray, S. A., Winkelman, L. G., Heuman, D. M., Wrighton, S. A., & Guzelian, P. S. (1989) · Journal of Clinical Investigation · doi:10.1172/jci113933 · Cited by 345
Cytochrome P450 phenotypic ratios for predicting herb‐drug interactions in humans
Gurley, B. J., Gardner, S. F., Hubbard, M. A., Williams, D. K., Gentry, W. B., Cui, Y., & Ang, C. Y. W. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.126913 · Cited by 343
Madan, A., Graham, R. A., Carroll, K. M., Mudra, D. R., Burton, L. A., Krueger, L. A., Downey, A. D., Czerwinski, M., Forster, J., Ribadeneira, M. D., et al. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.4.421 · Cited by 338
CYP3A4 drug interactions: correlation of 10 in vitro probe substrates
Kenworthy, Bloomer, Clarke, & Houston (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00073.x · Cited by 336
Kodama, S., Koike, C., Negishi, M., & Yamamoto, Y. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.18.7931-7940.2004 · Cited by 334
Murk, A. (1996) · Fundamental and Applied Toxicology · doi:10.1006/faat.1996.0152 · Cited by 334
Eagling, V. A., Back, D. J., & Barry, M. G. (1997) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1997.00644.x · Cited by 333
Ogilvie, B. W., Zhang, D., Li, W., Rodrigues, A. D., Gipson, A. E., Holsapple, J., Toren, P., & Parkinson, A. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.007633 · Cited by 330
Yuan, R., Madani, S., Wei, X.-X., Reynolds, K., & Huang, S.-M. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.12.1311 · Cited by 325
Schmiedlin-Ren, P., Thummel, K. E., Fisher, J. M., Paine, M. F., Lown, K. S., & Watkins, P. B. (1997) · Molecular Pharmacology · doi:10.1124/mol.51.5.741 · Cited by 325
Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s
Waxman, D. J., Lapenson, D. P., Aoyama, T., Gelboin, H. V., Gonzalez, F. J., & Korzekwa, K. (1991) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(91)90602-f · Cited by 324
Roy, P., Yu, L. J., Crespi, C. L., & Waxman, D. J. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15302-0 · Cited by 320
Distlerath, L. M., Reilly, P. E., Martin, M. V., Davis, G. G., Wilkinson, G. R., & Guengerich, F. P. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)39456-5 · Cited by 319
Metabolism of melatonin by human cytochromes p450
Ma, X., Idle, J. R., Krausz, K. W., & Gonzalez, F. J. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.002410 · Cited by 319
Expression and Regulation of Xenobiotic-Metabolizing Cytochrome P450 (CYP) Enzymes in Human Lung
Hukkanen, J., Pelkonen, O., Hakkola, J., & Raunio, H. (2002) · Critical Reviews in Toxicology · doi:10.1080/20024091064273 · Cited by 318
Self-citationSpecificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2.
Tassaneeyakul, W., Birkett, D. J., Veronese, M. E., McManus, M. E., Tukey, R. H., Quattrochi, L. C., Gelboin, H. V., & Miners, J. O. (1993) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38136-x · Cited by 316
The intralobular distribution of ethanol-inducible P450IIE1 in rat and human liver
Tsutsumi, M., Lasker, J. M., Shimizu, M., Rosman, A. S., & Lieber, C. S. (1989) · Hepatology · doi:10.1002/hep.1840100407 · Cited by 315
Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.
Bertilsson, L., Carrillo, J., Dahl, M.-L., LLerena, A., Alm, C., Bondesson, U., Lindström, L., de la Rubia, I. R., Ramos, S., & Benítez, J. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04385.x · Cited by 307
Oxidation of quinidine by human liver cytochrome P-450.
Guengerich, F. P., Müller-Enoch, D., & Blair, I. A. (1986) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10372-6 · Cited by 304
Cell Lines: A Tool for In Vitro Drug Metabolism Studies
Gomez-Lechon, M., Donato, M., Lahoz, A., & Castell, J. (2008) · Current Drug Metabolism · doi:10.2174/138920008783331086 · Cited by 300
Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9
Baldwin, S. J., Bloomer, J. C., Smith, G. J., Ayrton, A. D., Clarke, S. E., & Chenery, R. J. (1995) · Xenobiotica · doi:10.3109/00498259509061850 · Cited by 298
Pascussi, J.-M., Gerbal-Chaloin, S., Duret, C., Daujat-Chavanieu, M., Vilarem, M.-J., & Maurel, P. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105349 · Cited by 298
Faucette, S. R., Zhang, T.-C., Moore, R., Sueyoshi, T., Omiecinski, C. J., LeCluyse, E. L., Negishi, M., & Wang, H. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.112136 · Cited by 294
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin
Schneck, D. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.014 · Cited by 292
Li, X.-Q., Björkman, A., Andersson, T. B., Ridderström, M., & Masimirembwa, C. M. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.2.399 · Cited by 288
Hijazi, Y., & Boulieu, R. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.7.853 · Cited by 287
Campard, D., Lysy, P. A., Najimi, M., & Sokal, E. M. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.12.024 · Cited by 287
Tucker, G. T., Houston, J. B., & Huang, S. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.temp.1441.x · Cited by 284
Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes.
Nakajima, M., Yamamoto, T., Nunoya, K., Yokoi, T., Nagashima, K., Inoue, K., Funae, Y., Shimada, N., Kamataki, T., & Kuroiwa, Y. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12887-5 · Cited by 284
Assessment of CYP1A2 Activity in Clinical Practice: Why, How, and When?
Faber, M. S., Jetter, A., & Fuhr, U. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto_973160.x · Cited by 283
EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRO
Dai, Y., Hebert, M. F., Isoherranen, N., Davis, C. L., Marsh, C., Shen, D. D., & Thummel, K. E. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008680 · Cited by 279
Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene
Guengerich, F. P. (1990) · Chemical Research in Toxicology · doi:10.1021/tx00016a015 · Cited by 279
Takagi, S., Nakajima, M., Mohri, T., & Yokoi, T. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709382200 · Cited by 278
Song, B. J., Veech, R. L., Park, S. S., Gelboin, H. V., & Gonzalez, F. J. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)94103-7 · Cited by 277
57 Varieties: The Human Cytochromes P450
Lewis, D. F. (2004) · Pharmacogenomics · doi:10.1517/phgs.5.3.305.29827 · Cited by 277
HENGSTLER, J. G., UTESCH, D., STEINBERG, P., PLATT, K. L., DIENER, B., RINGEL, M., SWALES, N., FISCHER, T., BIEFANG, K., GERL, M., et al. (2000) · Drug Metabolism Reviews · doi:10.1081/dmr-100100564 · Cited by 277
ROLE OF ITRACONAZOLE METABOLITES IN CYP3A4 INHIBITION
Isoherranen, N., Kunze, K. L., Allen, K. E., Nelson, W. L., & Thummel, K. E. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000315 · Cited by 276
Stereoselective Metabolism of Omeprazole by Human Cytochrome P450 Enzymes
Äbelö, A., Andersson, T. B., Antonsson, M., Naudot, A. K., Skånberg, I., & Weidolf, L. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15171-9 · Cited by 276
Niwa, T., Shiraga, T., & Takagi, A. (2005) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.28.1805 · Cited by 274
Jiang, X., Williams, K. M., Liauw, W. S., Ammit, A. J., Roufogalis, B. D., Duke, C. C., Day, R. O., & McLachlan, A. J. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2003.02051.x · Cited by 274
Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver
Schuetz, J. D., Beach, D. L., & Guzelian, P. S. (1994) · Pharmacogenetics · doi:10.1097/00008571-199402000-00002 · Cited by 273
Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients.
Mollerup, S., Ryberg, D., Hewer, A. J., Phillips, D. H., & Haugen, A. (1999) · PubMed · Cited by 272
Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor Antagonist
Dingemanse, J., & van Giersbergen, P. L. M. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443150-00003 · Cited by 272
Database analyses for the prediction of in vivo drug–drug interactions from in vitro data
Ito, K., Brown, H. S., & Houston, J. B. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2003.02041.x · Cited by 272
(1997) · PubMed · Cited by 271
Leemann, T., Transon, C., & Dayer, P. (1993) · Life Sciences · doi:10.1016/0024-3205(93)90285-b · Cited by 267
Bioactivation of Halogenated Hydrocarbons by Cytochrome P4502E1
Raucy, J. L., Kraner, J. C., & Lasker, J. M. (1993) · Critical Reviews in Toxicology · doi:10.3109/10408449309104072 · Cited by 265
Patki, K. C., von Moltke, L. L., & Greenblatt, D. J. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.7.938 · Cited by 263
Huang, Z., Roy, P., & Waxman, D. J. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00410-4 · Cited by 263
Inhibition of cytochrome P-450 2E1 by diallyl sulfide and its metabolites
Brady, J. F., Ishizaki, H., Fukuto, J. M., Lin, M. C., Fadel, A., Gapac, J. M., & Yang, C. S. (1991) · Chemical Research in Toxicology · doi:10.1021/tx00024a008 · Cited by 262
Boobis, A. R., Lynch, A. M., Murray, S., de la Torre, R., Solans, A., Farré, M., Segura, J., Gooderham, N. J., & Davies, D. S. (1994) · PubMed · Cited by 261
The Discovery of the Microsomal Ethanol Oxidizing System and Its Physiologic and Pathologic Role
Lieber, C. S. (2004) · Drug Metabolism Reviews · doi:10.1081/dmr-200033441 · Cited by 259
Koudriakova, T., Iatsimirskaia, E., Utkin, I., Gangl, E. T., Vouros, P., Storozhuk, E., Orza, D., Marinina, J., & Gerber, N. (1998) · PubMed · Cited by 259
Westlind-Johnsson, A., Malmebo, S., Johansson, A., Otter, C., Andersson, T. B., Johansson, I., Edwards, R. J., Boobis, A. R., & Ingelman-Sundberg, M. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.6.755 · Cited by 258
Polymorphic CYP2B6: Molecular Mechanisms and Emerging Clinical Significance
Zanger, U. M., Klein, K., Saussele, T., Blievernicht, J., H Hofmann, M., & Schwab, M. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.7.743 · Cited by 258
Cresteil, T., Monsarrat, B., Alvinerie, P., Tréluyer, J., Vieira, I., & Wright, M. (1994) · PubMed · Cited by 257
Zhou, C. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27793 · Cited by 256
von Richter, O., Burk, O., Fromm, M. F., Thon, K. P., Eichelbaum, M., & Kivistö, K. T. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.10.008 · Cited by 255
Behnisch, P. A., Hosoe, K., & Sakai, S.-I. (2001) · Environment International · doi:10.1016/s0160-4120(01)00028-9 · Cited by 254
Pharmacokinetic Interactions of Drugs with St John’s Wort
Zhou, S., Chan, E., Pan, S.-Q., Huang, M., & Lee, E. J. D. (2004) · Journal of Psychopharmacology · doi:10.1177/0269881104042632 · Cited by 253
Chang, T. K. H., Gonzalez, F. J., & Waxman, D. J. (1994) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1994.1259 · Cited by 251
Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors
Ernest, C. S., Hall, S. D., & Jones, D. R. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.075416 · Cited by 246
Code, E. L., Crespi, C. L., Penman, B. W., Gonzalez, F. J., Chang, T. K. H., & Waxman, D. J. (1997) · PubMed · Cited by 245
Gurley, B. J., Gardner, S. F., Hubbard, M. A., Williams, D. K., Gentry, W. B., Cui, Y., & Ang, C. Y. W. (2005) · Drugs & Aging · doi:10.2165/00002512-200522060-00006 · Cited by 244
Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes
Hollenberg, P. F. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001387 · Cited by 243
Human hepatocytes as a tool for studying toxicity and drug metabolism
Gomez-Lechon, M., Donato, M., Castell, J., & Jover, R. (2003) · Current Drug Metabolism · doi:10.2174/1389200033489424 · Cited by 242
Rifampin drastically reduces plasma concentrations and effects of oral midazolam
Backman, J. T., Olkkola, K. T., & Neuvonen, P. J. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90018-1 · Cited by 242
Rasmussen (2002) · Pharmacogenetics · doi:10.1097/00008571-200208000-00008 · Cited by 241
Antiepileptic Drugs Increase Plasma Levels of 4β-Hydroxycholesterolin Humans
Bodin, K., Bretillon, L., Aden, Y., Bertilsson, L., Broomé, U., Einarsson, C., & Diczfalusy, U. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105127200 · Cited by 241
Human Cytochrome P-450 3A4: In Vitro Drug-Drug Interaction Patterns Are Substrate-Dependent
Wang, R. W., Newton, D. J., Liu, N., Atkins, W. M., & Lu, A. Y. H. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15374-3 · Cited by 240
The Safety of Newly Approved Medicines: Do Recent Market Removals Mean There Is a Problem?
Friedman, M. A., Woodcock, J., Lumpkin, M. M., Shuren, J. E., Hass, A. E., & Thompson, L. J. (1999) · JAMA · doi:10.1001/jama.281.18.1728 · Cited by 238
CYP2A6: a human coumarin 7-hydroxylase
Pelkonen, O., Rautio, A., Raunio, H., & Pasanen, M. (2000) · Toxicology · doi:10.1016/s0300-483x(99)00200-0 · Cited by 236
Self-citationJacobsen, W., Kuhn, B., Soldner, A., Kirchner, G., Sewing, K.-F., Kollman, P. A., Benet, L. Z., & Christians, U. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15086-6 · Cited by 236
Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone
Baldwin, Clarke, & Chenery (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00030.x · Cited by 235
Molecular and physical mechanisms of first-pass extraction.
Hall, S. D., Thummel, K. E., Watkins, P. B., Lown, K. S., Benet, L. Z., Paine, M. F., Mayo, R. R., Turgeon, D. K., Bailey, D. G., Fontana, R. J., et al. (1999) · PubMed · Cited by 235
Aoyama, T., Yamano, S., Guzelian, P. S., Gelboin, H. V., & Gonzalez, F. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.12.4790 · Cited by 235
Sesardic, D., Boobis, A., Edwards, R., & Davies, D. (1988) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1988.tb03393.x · Cited by 233
Li, X.-Q., Bj�rkman, A., Andersson, T. B., Gustafsson, L. L., & Masimirembwa, C. M. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0636-9 · Cited by 232
Ma, Q. (2001) · Current Drug Metabolism · doi:10.2174/1389200013338603 · Cited by 232
Identification of Human Liver Cytochrome P450 Isoforms Mediating Omeprazole Metabolism
ANDERSSON, T., MINERS, J. O., VERONESE, M. E., TASSANEEYAKUL, W., TASSANEEYAKUL, W., MEYER, U. A., & BIRKETT, D. J. (1993) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1993.tb00410.x · Cited by 230
Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C
Hamman, M. A., Thompson, G. A., & Hall, S. D. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00143-3 · Cited by 230
L??pez-Cort??s, L. F., Ruiz-Valderas, R., Viciana, P., Alarc??n-Gonz??lez, A., G??mez-Mateos, J., Le??n-Jimenez, E., Sarasanacenta, M., L??pez-Pua, Y., & Pach??n, J. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241090-00004 · Cited by 229
Hakkola, J., Pelkonen, O., Pasanen, M., & Raunio, H. (1998) · Critical Reviews in Toxicology · doi:10.1080/10408449891344173 · Cited by 229
Self-citationInhibition Selectivity of Grapefruit Juice Components on Human Cytochromes P450
Tassaneeyakul, W., Guo, L.-Q., Fukuda, K., Ohta, T., & Yamazoe, Y. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2000.1835 · Cited by 229
Takahashi, T., Lasker, J. M., Rosman, A. S., & Lieber, C. S. (1993) · Hepatology · doi:10.1002/hep.1840170213 · Cited by 228
A Structural Basis for Constitutive Activity in the Human CAR/RXRα Heterodimer
Xu, R. X., Lambert, M. H., Wisely, B. B., Warren, E. N., Weinert, E. E., Waitt, G. M., Williams, J. D., Collins, J. L., Moore, L. B., Willson, T. M., et al. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.11.042 · Cited by 226
von Moltke, L. L., Greenblatt, D. J., Harmatz, J. S., Duan, S. X., Harrel, L. M., Cotreau-Bibbo, M. M., Pritchard, G. A., Wright, C. E., & Shader, R. I. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12284-2 · Cited by 225
Andersson, T., Miners, J., Veronese, M., & Birkett, D. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04336.x · Cited by 225
Cytochrome P450 2C8: Substrates, inhibitors, pharmacogenetics, and clinical relevance
TOTAH, R., & RETTIE, A. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.12.267 · Cited by 225
Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man
Veseli, E. S., & Page, J. G. (1969) · Journal of Clinical Investigation · doi:10.1172/jci106186 · Cited by 223
Impact of CYP2B6 Polymorphism on Hepatic Efavirenz Metabolism in Vitro
Desta, Z., Saussele, T., Ward, B., Blievernicht, J., Li, L., Klein, K., Flockhart, D. A., & Zanger, U. M. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.6.547 · Cited by 222
Cytochromes P450 in the Bioactivation of Chemicals
Ioannides, C., & V. Lewis, D. (2004) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026043387188 · Cited by 220
von Moltke, L. L., Greenblatt, D. J., Schmider, J., Duan, S. X., Wright, C. E., Harmatz, J. S., & Shader, R. I. (1996) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1996.tb04251.x · Cited by 218
Li, T., & Chiang, J. Y. L. (2005) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00258.2004 · Cited by 218
Contribution of CYP3A5 to the in Vitro Hepatic Clearance of Tacrolimus
Kamdem, L. K., Streit, F., Zanger, U. M., Brockmöller, J., Oellerich, M., Armstrong, V. W., & Wojnowski, L. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2005.050047 · Cited by 218
Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline
Kunze, K. L., & Trager, W. F. (1993) · Chemical Research in Toxicology · doi:10.1021/tx00035a009 · Cited by 216
CYP1A Induction and Human Risk Assessment: An Evolving Tale of in Vitro and in Vivo Studies
Ma, Q., & Lu, A. Y. H. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.015826 · Cited by 215
HepaRG Cells as an in Vitro Model for Evaluation of Cytochrome P450 Induction in Humans
Kanebratt, K. P., & Andersson, T. B. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.017418 · Cited by 214
Cited by
Cytochrome P450 Enzymes and Drug Metabolism in Humans
Zhao, M., Ma, J., Li, M., Zhang, Y., Jiang, B., Zhao, X., Huai, C., Shen, L., Zhang, N., He, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312808 · Cited by 1,070
“It is mostly transcriptional regulation, and mainly resulting from epigenetic regulation, although non-transcriptional mechanisms, such as enzyme stabilization, stabilization of mRNA, or inhibition of protein degradation, have also been reported [94].”
BackgroundAlternative (non-animal) methods for cosmetics testing: current status and future prospects—2010
Adler, S., Basketter, D., Creton, S., Pelkonen, O., van Benthem, J., Zuang, V., Andersen, K. E., Angers-Loustau, A., Aptula, A., Bal-Price, A., et al. (2011) · Archives of Toxicology · doi:10.1007/s00204-011-0693-2 · Cited by 584
Self-citationEsteves, F., Rueff, J., & Kranendonk, M. (2021) · Journal of Xenobiotics · doi:10.3390/jox11030007 · Cited by 512
Biotransformation of Xenobiotics
Timbrell, J. A., & Marrs, T. C. (2009) · General, Applied and Systems Toxicology · doi:10.1002/9780470744307.gat004 · Cited by 435
Inhibition and induction of CYP enzymes in humans: an update
Hakkola, J., Hukkanen, J., Turpeinen, M., & Pelkonen, O. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02936-7 · Cited by 418
Self-citation
Metadata
- Authors
- Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., & Raunio, H.
- Venue
- Archives of Toxicology
- Published
- 2008-07-11
- Volume
- 82
- Issue
- 10
- Pages
- 667-715
- ISSN
- 0340-5761 (ISSN-L)
- 1432-0738
- OpenAlex
- W2034400329
- Cited by
- 569
- References
- 582
- FWCI
- 36.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.